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Strengths and limitations of this study
 ► This is a national population- based study based on 
objective pharmacy claims data.
 ► Epidemiological data on the prevalence and inci-
dence of type 1 diabetes in Ireland are limited, and 
this study provides important information for nation-
al resource planning and for comparison with inter-
national studies.
 ► Data across all age groups were included in contrast 
to previous studies focused only on paediatric type 
1 diabetes.
 ► The study is limited by the duration of only 6 years 
of continuous data on pharmacy claims and by the 
lack of external validation due to the absence of a 
national diabetes register in Ireland.
AbStrACt
Objectives The aim of this study is to estimate the 
prevalence and incidence of type 1 diabetes in the Irish 
population using a national pharmacy claims database in 
the absence of a national diabetes register.
Design National, population- based, retrospective, cross- 
sectional study.
Setting Community care with data available through the 
Health Service Executive Pharmacy Claims Reimbursement 
Scheme from 2011 to 2016.
Participants Individuals with type 1 diabetes were 
identified by coprescription of insulin and glucometer test 
strips without any prolonged course (>12 months) of oral 
hypoglycaemic agents prior to commencing insulin. Those 
claiming prescriptions for long- acting insulin only, without 
any prandial insulin, were excluded from the analysis. 
Incidence was estimated based on the first claim for 
insulin in 2016, with no insulin use in the preceding 12 
months.
Main outcome measures Prevalence of type 1 diabetes 
in children (<18 years) and adults (≥18 years); incidence 
of type 1 diabetes in children (≤14 years) and adolescents 
and adults (>14 years).
results There were 20 081 prevalent cases of type 1 
diabetes in 2016. The crude prevalence was 0.42% (95% 
CI 0.42% to 0.43%). Most prevalent cases (n=17 053, 85%) 
were in adults with a prevalence of 0.48% (95% CI 0.47% 
to 0.48%). There were 1527 new cases of type 1 diabetes in 
2016, giving an incidence rate of 32 per 100 000 population/
year (95% CI 30.5 to 33.7). There was a significant positive 
linear trend for age, for prevalence (p<0.0001) and incidence 
(p=0.014). The prevalence and incidence were 1.2- fold and 
1.3- fold higher in men than women, respectively. Significant 
variations in prevalence (p<0.0001) and incidence (p<0.001) 
between the different geographical regions were observed.
Conclusions This study provides epidemiological 
estimates of type 1 diabetes across age groups in Ireland, 
with the majority of prevalent cases in adults. Establishing 
a national diabetes register is essential to enable updated 
epidemiological estimates of diabetes and for planning of 
services in Ireland.
IntrODuCtIOn
The prevalence and incidence of diabetes 
is increasing worldwide. In 2017, the 
International Diabetes Federation estimated 
that there were 425 million adults aged 20–79 
years with diabetes (all types).1 The patho-
physiology of type 1 diabetes is different from 
type 2 diabetes: it is an autoimmune condi-
tion, characterised by destruction of pancre-
atic beta cells, resulting in absolute insulin 
deficiency, whereas type 2 diabetes is charac-
terised by a combination of insulin resistance 
and inadequate insulin secretion to meet the 
body’s needs.2 Type 2 diabetes accounts for 
the vast majority of cases while type 1 diabetes 
accounts for approximately 5%–10% of the 
total population of people with diabetes.2 The 
epidemiology of type 1 diabetes is, however, 
best described in children aged ≤14 years of 
age2 through three international population- 
based studies: DIAMOND Project, EURO-
DIAB and the SEARCH for Diabetes in 
Youth,3–6 and the incidence is increasing by 
approximately 3% (or more) a year.7
The paucity of data available on incidence 
and prevalence of type 1 diabetes in adults 
was highlighted in a recent systematic review 
on this topic.5 Information on adult type 
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1 diabetes (including adolescents aged >14 years) was 
provided in only 35 countries, whereas information on 
paediatric diabetes (children aged 14 years and under) 
was available in 88 countries.5 Although type 1 diabetes 
has traditionally been called ‘juvenile diabetes’ and 
considered as a disease of childhood, recent evidence 
suggests that it presents in adults more commonly than 
previously believed.2 Approximately one quarter of those 
with type 1 diabetes are diagnosed as adults,4 and adults 
aged ≥20 years account for more than a million people 
(85% of the total) with type 1 diabetes in the USA.8 
Similarly, analysis of 60 years of data in the UK Biobank 
suggests that as many as half of all incident cases of type 
1 diabetes were diagnosed in adulthood.9 Incidence rates 
in adult populations are rarely available, in part due to 
the difficulty in distinguishing type 1 diabetes from type 
2 diabetes requiring insulin treatment.5 In addition, 
more than 20% of adults with type 2 diabetes may also be 
receiving insulin.10
Although evidence is scarce, of those studies avail-
able prevalence and incidence of type 1 diabetes have 
usually been based on data from national (eg, UK and 
Denmark)11 12 or local (eg, Italy)13 diabetes registries, 
national surveys (eg, Canada and Scotland)14 15 or 
hospital/GP records (eg, Lithuania and Iraq).16–18 Use of 
medication or claims data is relatively uncommon. In a 
systematic review of the incidence of type 1 diabetes in 
people aged ≤34 years, only 13% of the 71 reviewed arti-
cles used drug registries to obtain epidemiological data.5 
Currently, there is no diabetes register in Ireland, and 
previously only two studies have examined the prevalence 
of type 1 diabetes in adults: one was based on a survey 
of Irish diabetes clinics (self- reports),19 20 and the other 
on a mathematical model,21 but both with limitations to 
study design and approach taken. In addition, although 
a systematic review on the prevalence of diabetes in 
the adult population in Ireland was published recently, 
studies focused solely on type 1 diabetes were excluded.22 
According to this systematic review, the overall preva-
lence of adult diabetes in Ireland was 5.2% in 2015, but 
there was no differentiation between type 1 and type 2 
diabetes.22 The aim of this study is to estimate the preva-
lence and incidence of type 1 diabetes in the Irish popu-
lation across all ages using a national pharmacy claims 
database.
MethODS
A retrospective cross- sectional study was conducted 
using the Irish Health Service Executive Primary Care 
Reimbursement Service (HSE- PCRS) national pharmacy 
claims database from the years 2011–2016.
Settings/data sources
The HSE- PCRS pharmacy claims database is primarily for 
administrative purposes and collates basic demographic 
information and details on monthly dispensed medica-
tions from the main community drug schemes including 
the Drug Payment (DP), General Medical Services (GMS) 
and Long- Term Illness (LTI) schemes.23 The DP scheme 
provides medicines to all Irish residents not covered by 
either the GMS or LTI schemes. There was a monthly 
out- of- pocket cost per family of up to €144 per month 
(at the time of the study). The GMS scheme (‘medical 
card’) is based on means and age; the means testing is 
based on the weekly income threshold and increased 
for those aged over 70 years23 24 with a small copayment 
applied to each item.23 The LTI scheme does not include 
means testing and provides free medication for 16 speci-
fied chronic illnesses including diabetes.23 25 Patients with 
diabetes under the LTI scheme have their medicines- 
related costs fully covered by the state (including insulin, 
oral hypoglycaemic agents (OHAs), glucometer test 
strips, needles, infusion sets and so on); therefore, they 
have no medicine- related out- of- pocket expenses.
All prescription items in the HSE- PCRS pharmacy claims 
database are coded using the WHO’s Anatomical Thera-
peutic Chemical (ATC) classification,26 and the database 
contains basic demographic information including age, 
sex and region of residence.27 The HSE- PCRS database 
has previously been used to investigate type 2 diabetes- 
related prescriptions.27
Study population
The study population consists of all those with diabetes 
who were eligible for inclusion in the GMS and LTI 
schemes and who received at least one prescription for 
medication for diabetes, according to the WHO ATC 
codes for diabetes (A10)26 in years 2011–2016. As the 
financial burden of diabetes- related medicines is signifi-
cant in Ireland, all those who receive their diabetes care 
(either through the primary care or hospital diabetes 
clinics) are advised to apply for either the LTI or GMS 
scheme from their initial visit. Therefore, we assume that 
these schemes cover the entire population with diabetes 
who have been prescribed and dispensed the diabetes- 
related medicines in Ireland.
ethical approval
The data are all anonymised and permission was obtained 
from the data controllers (HSE- PCRS) for use of the data. 
As it was a secondary data analysis of a fully anonymised 
dataset, ethical approval was not required.
Patient and public involvement
No patients or the public were involved in the study 
protocol design, the specific aims or research questions 
development, or in developing plans for recruitment, 
design, or implementation of the study. No patients were 
asked to advise on interpretation or writing.
Definitions
To differentiate type 1 from other types of diabetes, 
we used case definition criteria based on the review of 
existing definitions and algorithms28–35 and available 
clinical guidelines for type 1 diabetes treatment. None of 
the existing algorithms were suitable to use in the Irish 
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Figure 1 Flow chart presenting the definition of the prevalent and incident cases of type 1 diabetes based on the pharmacy 
claims database. OHA, oral hypoglycaemic agent.
context for a variety of reasons. We decided to focus 
on clinical guidelines and type 1 diabetes specific treat-
ment and use a Klompas’s algorithm as a guide.34 This 
algorithm helps to identify type 1 diabetes from type 2 
diabetes based on chart review and different inclusion 
(insulin, urine test strips and glucagon) and exclusion 
criteria (OHA, excluding metformin). As no official 
guidelines existed for the treatment of type 1 diabetes in 
Ireland at the time of the study, we used the American 
Diabetes Association36 and the UK National Institute for 
Health and Care Excellence (NICE) guidelines.37 Initial 
analyses of different definitions and the use of a very 
detailed, and prescription- based, Klompas’s algorithm34 
guided us to use insulin and blood glucose test strips 
only and to exclude people on prolonged treatment of 
OHA prior to commencing insulin. We also excluded 
those patients receiving prescriptions for long- acting 
(basal) insulin only, without any prescription for pran-
dial insulin, as these people are more likely to have type 
2 diabetes than type 1 diabetes.38 39 After initial analysis of 
different definitions based on the type 1 diabetes specific 
treatment schemes (online supplementary table 1), algo-
rithms (online supplementary table 2) and comparisons 
with other existing evidence,28–35 the following definition 
was used (see figure 1).
Statistical analysis
Data analysis included descriptive statistics (proportions 
or percentages) with 95% CIs where appropriate. Crude 
number and rates of incident and prevalent cases in 2016 
are presented and stratified by age groups (0–14, 15–24, 
25–34, 35–44, 45–54, 55–64, 65–74 and 75+ years), region 
of residence and gender. In addition, the prevalence was 
calculated for individuals under 18 years (children and 
adolescents) and for adults (aged 18 years and over), 
and incidence was calculated for children up to (and 
including) 14 years and adults and adolescents 15 years 
and over to allow international comparison with existing 
evidence. The 2016 Central Statistics Office ( www. cso. 
ie) data were used for the calculation of age- specific 
rates (denominators for population numbers), and the 
overall prevalence and incidence rates for the population 
were age standardised to the European standard popu-
lation for international comparison.40 χ2 tests were used 
to compare differences in prevalence for age (Cochran- 
Armitage trend test was used for linear trend), region 
and gender. Negative binomial regression was used to 
compare incidence rate across age, region and gender. 
Significance at p<0.05 was assumed. SAS statistical soft-




A total of 20 081 individuals met the definition for prev-
alent type 1 diabetes in 2016 in Ireland providing an 
overall crude population prevalence of 0.42% (95% 
CI 0.42% to 0.43%). The crude prevalence rate was 
significantly lower in those <18 years of age compared 
with adults aged 18 years and over (table 1). The age- 
standardised prevalence rate for the population was 
0.45% (95% CI 0.44% to 0.46%). The prevalence 
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Table 1 Prevalence of type 1 diabetes in the Irish population in 2016 stratified by age group
Age group Prevalent cases
Population
(Census 2016) Prevalence (%) 95% CI (%)
0–14* 1846 1 006 552 0.18* 0.18 to 0.19
15–24* 2182 576 452 0.38* 0.36 to 0.39
25–34* 2363 659 410 0.36* 0.34 to 0.37
35–44* 2831 746 881 0.38* 0.37 to 0.39
45–54* 2897 626 045 0.46* 0.45 to 0.48
55–64* 2889 508 958 0.57* 0.55 to 0.59
65–74* 2688 373 508 0.72* 0.69 to 0.75
75+* 1948 264 059 0.74* 0.71 to 0.77
Total – C†‡ 20 081†‡ 4 761 865 0.42†‡ 0.42 to 0.43†‡
Total – S†§ 20 081†§ 4 761 865 0.45†§ 0.44 to 0.46†§
<18 years¶ 2591 1 188 242 0.22¶ 0.21 to 0.23¶
≥18 years¶ 17 053 3 573 623 0.48¶ 0.47 to 0.48¶
*Significant increasing prevalence with age (χ2=54.6, p<0.0001)
†There were 437 missing data for age (2%). The data are included in the total number of prevalent cases.
‡Total – C (crude): crude prevalence.
§Total – S (standardised): prevalence (%) age- standardised to the European Standard Population 2013.
¶ Significant difference between <18 and ≥18 years (χ2=1500, p<0.001).
Table 2 Number of new cases and incidence rate (per 100 000 population per year) of type 1 diabetes in the Irish population 
in 2016
Age group Incident cases Population (Census 2016)
Incident rate per 100 000 
population/year 95% CI
0–14* 319 1 006 552 31.69* 28.21 to 35.17
15–24* 155 576 452 26.89* 22.66 to 31.12
25–34* 197 659 410 29.88* 25.70 to 34.05
35–44* 233 746 881 31.20* 27.19 to 35.20
45–54* 150 626 045 23.96* 20.13 to 27.79
55–64* 152 508 958 29.86* 25.12 to 34.61
65–74* 154 373 508 41.23* 34.72 to 47.74
75+* 143 264 059 54.15* 45.28 to 63.03
TOTAL – C†‡ 1527†‡ 4 761 865 32.07†‡ 30.46 to 33.68†‡
TOTAL – S†§ 1527†§ 4 761 865 32.56†§ 30.92 to 34.19†§
≤14 years 319 1 006 552 31.69 20.66 to 4273
>14 years 1184 3 755 313 31.53 20.52 to 42.53
*Significant increasing incidence with age (p=0.014).
†There were 24 missing data for age (2%) for incidence. The data are included in the total number of incident cases.
‡Total – C (crude): crude prevalence.
§Total – S (standardised): incident rate per 100 000 population/year, age- standardised to the European Standard Population 2013.
was significantly higher in men than women 0.46% vs 
0.37% (p<0.0001). Age- standardised prevalence of men 
and women was 0.51% and 0.39%, respectively. Of all 
prevalent cases, 55% were men. The age- adjusted prev-
alence was the highest in the oldest age groups, and the 
lowest in children under ≤14 years (table 1). There was 
a significant increasing prevalence with increasing age 
(table 1). Significant variation in prevalence between 
the different geographical regions was observed ranging 
from 0.34% to 0.56% (χ2=191.64, p<0.0001) across all 
ages. There was a 2.5- fold variation in the prevalence 
in those under 18 years between geographical regions 
(online supplementary table 3).
Incidence
There were 1527 incident cases, giving a crude incidence 
rate of 32.07 (95% CI 30.46 to 33.68) per 100 000 persons 
per year for the population (table 2). The age- standardised 
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incidence for the population was 32.56 (95% CI 30.92 to 
34.10) per 100 000 persons per year.
There were significantly more incident cases in men 
(n=820) than in women (n=681) in 2016, giving inci-
dence rates of 34.83 versus 28.29 per 100 000 population/
year, respectively (p=0.03). The age- standardised inci-
dence was 36.37/100 000 population/year in men versus 
28.80/100 000 population/year in women. Of all incident 
cases, 1184 (78%) were in adults and adolescents aged 
>14 years, compared with 319 (21%) in children aged ≤14 
years. The crude incidence rate was 31.69 for those aged 
≤14 years and 31.53 per 100 000 persons/per year in those 
aged over 14 years but not significantly different (table 2). 
There was a significant increasing incidence with age. 
The highest incidence was observed in children aged ≤14 
years, adults aged 33–44 years and older adults aged 75 
years and over (table 2). Significant variation in the inci-
dence rates between different geographical regions was 
observed ranging from 22.86 to 53.54 per 100 000 popu-
lation per year across all ages (p<0.001). There was an 
almost fivefold regional variations observed in children 
aged ≤14 years and more than twofold variation in adoles-
cents and adults aged >14 years (online supplementary 
table 3).
DISCuSSIOn
Based on pharmacy claims data, this national study esti-
mated the overall prevalence of type 1 diabetes in Ireland 
as 0.45%, and it increases with age. The prevalence in 
adults was 0.48% with the highest number of prevalent 
cases being observed in the 45–54 years age group. The 
prevalence was significantly higher in men than women 
(0.51% vs 0.39%), giving a male- to- female ratio of 1.2. 
The prevalence was also significantly higher in adults 
than children and adolescents under 18 years. The 
current study also estimated the incidence rate as 32.07 
per 100 000 population/year and was similar for both 
children and adolescents/adults. The incidence was also 
significantly higher in men than women in all age groups 
over 14 years of age. Significant variation was observed 
between different geographical regions.
To date, there are only two studies available against 
which to validate our findings in the adult population in 
Ireland. The most recent, a National Survey of Diabetes 
Care Delivery in Acute Hospitals19 20 initially found that 
there were 19 748 adults with type 1 diabetes in Ireland, 
and these data were used as estimates for the ‘Adult type 
1 diabetes mellitus’ national clinical guidelines of care41 
and budget impact analysis.19 These data, however, may 
not be accurate as only four of the 31 diabetes services 
provided actual figures, and others indicated that these 
were based on respondents’ ‘best estimates’;20 authors of 
the survey have not included these figures in their offi-
cial final report.20 Another study conducted in 2005 to 
estimate the epidemiology of type 1 diabetes in Ireland 
was based on a model using reference rates from a 
study conducted in Wales in 199821 and therefore was 
not considered comparable in 2016. Our findings bear 
comparison with other epidemiological evidence that 
exists in the paediatric population.42–44 The crude prev-
alence number (n=2591) that we have estimated appears 
to be close to other prevalence estimates, for example, 
from the Paediatric Diabetes National Audit (n=2632 in 
2013).42 43 Findings from the Irish Childhood Diabetes 
National Register, which mainly focuses on the incidence 
rather than prevalence,44 suggest that the crude incidence 
rate in children aged ≤14 years was 28.8 per 100 000 popu-
lation/year in 2013, compared with our estimate of 31.6 
per 100 000 population/year in 2016. This difference 
might reflect the trend of increasing incidence of type 1 
diabetes by at least 3% per year in Europe.7
This study contributes information about incidence 
and prevalence of type 1 diabetes in people of all ages, 
including those aged 18–64 years.5 It is interesting to note 
that 35% of incident cases were in the age group of 35–64 
years, in line with a recently published study using the UK 
Biobank, showing that as many as 42% of type 1 diabetes 
cases may be diagnosed between 31 years and 60 years 
of age.9 Another study from the UK suggests that type 
1 diabetes presenting in later life is often unrecognised 
or misdiagnosed as type 2 diabetes, despite the need to 
start insulin therapy soon after diagnosis.45 According 
to a study from Italy, there are peaks in the incidence of 
type 1 diabetes in different age groups, with the highest 
observed in children and adolescents under 15 years, 
then a significant decrease in age groups 15–29 years, 
followed by continuously increasing incidence from the 
age of 29–49 years.13 In that study, there were no data for 
older age groups, but our findings demonstrate a similar 
pattern across all the available comparable age groups.
The results of the current study show a gender distribu-
tion of prevalence and incidence of type 1 diabetes being 
more common in men than women, a finding that was also 
demonstrated by other studies.5 13 16 According to a review 
on gender effect,46 the ratio of male to female in adult 
onset type 1 diabetes ranged from 1.30 to 2.15, compared 
with a ratio of 1.2 in our study for both incidence and 
prevalence. However, this review only included ages up 
to 44 years, so is not directly comparable. According to 
a more recent analysis of the Swedish diabetes register,47 
incidence by gender in those aged 40 years or older was 
equally distributed among men and women, what may 
reduce the overall male- to- female ratio.
The prevalence rates correspond with data on the prev-
alence in adults, for example, in the USA from 2016 to 
17 (0.5% prevalence of type 1 diabetes in adult Ameri-
cans),48 but seem lower than in Scotland where a preva-
lence of type 1 diabetes of 0.6% for the whole population 
and 0.7% in adults was found.15 It is difficult to compare 
our findings with other international evidence as most 
previous studies were conducted in younger popula-
tions (children and young adults, and young adults).5 
For example, in a Canadian study, only those diagnosed 
with type 1 diabetes under 30 years were considered30 and 
those under 40 years of age were included in a USA- based 
copyright.
 on A











pen: first published as 10.1136/bm





6 Gajewska KA, et al. BMJ Open 2020;10:e032916. doi:10.1136/bmjopen-2019-032916
Open access 
study.49 Other epidemiological studies intentionally 
focused on particular age groups, that is, 15–34 years in 
Lithuania16 17 under 34 years in Sweden35 and under 40 
years in Iraq.18 In addition, the definition we used was 
more inclusive and based on real- world diabetes manage-
ment, not related to insulin intake only: for example, our 
definition did not exclude patients currently on insulin 
and OHA (metformin). NICE guidelines (2015)37 recom-
mend adding metformin to insulin therapy ‘if an adult 
with type 1 diabetes and a BMI of 25 kg/m2 (…) or above 
wants to improve their blood glucose control while mini-
mising their effective insulin dose’.37 According to find-
ings from the German diabetes registry, as many as 25.5% 
of patients with type 1 diabetes presented with the meta-
bolic syndrome (at least three criteria including body 
mass index >30 kg/m2).50 However, data on the preva-
lence of metformin use in adults with type 1 diabetes are 
currently lacking.50
The main strengths of this study include its population- 
based, nationwide character and use of objective phar-
macy claims data. Our study is the first study published 
since 2005 to present epidemiological evidence for adults 
with type 1 diabetes in Ireland and provides findings for 
the paediatric population that are comparable with the 
existing evidence. Therefore, we believe that the method 
we used to assess prevalence and incidence is currently the 
best available, in the absence of any local or national adult 
register in Ireland to use as a tool for validation. This study 
estimate the prevalence and incidence of type 1 diabetes 
in the entire population, not limited by age, providing 
useful information for national resource planning and 
for comparison with international studies. The definition 
criteria that we have used were based on other defini-
tions, clinical guidelines and real- world diabetes manage-
ment to be more inclusive to all, not only typical cases of 
type 1 diabetes. This study has some potential limitations. 
First, the analysis of the database was conducted over a 
relatively short timeframe (6 years, 2011–2016). There-
fore, in calculating prevalence, we may have misclassified 
some type 2 diabetes cases as type 1 if they had prolonged 
metformin use and had already progressed to basal- 
bolus insulin. Second, although the chosen definition of 
a person with type 1 diabetes was considered thorough 
and discussed with experts in the area (see Methods and 
online supplementary tables 1 and 2 for more details), 
some people may have been misclassified. Unlike other 
studies using pharmacy claims databases for epidemio-
logical estimates,28 35 we had no information (eg, ICD-10 
(International Statistical Classification of Diseases and 
Related Health Problems) codes or laboratory results) to 
confirm the diagnosis of type 1 diabetes. Therefore, it was 
not possible to distinguish less prevalent types of diabetes, 
such as Latent Autoimmune Diabetes of Adulthood from 
type 1 or gestational diabetes treated with insulin. Due to 
this limitation, we were also unable to track comorbidi-
ties and acute illness conditions other than diabetes that 
require diabetes- specific medicines. Moreover, we were 
unable to validate the pharmacy claims data, that is, based 
on the capture- recapture method.35 The HSE- PCRS data 
are anonymised so that access to patients’ individual elec-
tronic health data or hospital charts was not possible, and 
therefore, we could not confirm accuracy as was done in 
other studies.28 30 35 Another limitation is the possibility 
of overestimation of type 1 diabetes in the older aged 
population, particularly those over 70 years, who may be 
eligible for both LTI and GMS schemes at the same time 
and may have been double- counted. This may help to 
explain the high incidence rate in the older aged popu-
lation, which is higher, for example, in comparison with 
existing evidence on incidence rates in Scottish adults 
(ie, Scottish Diabetes Register 2017).15 When comparing 
with other international evidence or registries, our results 
appear consistent in the younger age groups. There are 
limited data on the incidence of type 1 diabetes in the 
adult population internationally against which to validate 
our findings.
Although our study has limitations, our findings provide 
supportive evidence that in a country without a national 
diabetes register or any other source of epidemiological 
data, routinely collected administrative pharmacy claims 
data may be a useful alternative to estimate the preva-
lence and incidence of conditions such as type 1 diabetes. 
Complete, national diabetes registries or pharmacy claims 
data are available only in some developed countries — in 
the majority of cases, databases are lacking (in particular 
in underdeveloped or developing countries), which might 
explain the scarcity of epidemiological evidence for type 
1 diabetes in populations across all ages. However, in the 
absence of alternative sources of epidemiological data 
such as registries, which may be considered more reliable, 
prescribing or pharmacy claims data may provide useful 
information for health service users and policy makers. 
Our study also highlights the need to establish a national 
diabetes register to continuously monitor the prevalence 
and incidence of diabetes in Ireland, diabetes- related 
outcomes and their burden.51 Finally, the findings of this 
study support the recent statements of a higher incidence 
of late- onset type 1 diabetes than previously assumed, which 
may have important implications for clinical practice. There 
is a need to further investigate the epidemiology of type 1 
diabetes in adults through both cross- sectional and longi-
tudinal analyses using nationally available datasets, such as 
diabetes registries, surveys, audits or pharmacy claims data, 
which will also allow for international comparisons. To vali-
date our findings, a diabetes register should be established 
or a different research approach, using biological markers 
(C- peptide levels or islet cell or GAD antibodies), should be 
conducted.
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